Generated by AI
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.
Website5850 San Felipe St.
Houston, TX, 77057
United States
The latest articles about COYA.
HOUSTON, November 10, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.
Summary of Nov 10's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about COYA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.